Interestingly, a subset of cases showed HER2 (human epidermal growth factor receptor 2) immunohistochemical positivity, suggesting the possibility of a targeted therapy as it could be performed in serous carcinoma [18,49]. Here, ERBB2 is linked to serous adenocarcinoma.